Teprotumumab, a human monoclonal anti-IGF-1R blocking antibody, reduced proptosis in a series of patients with non-inflammatory thyroid eye disease (TED), according to a study.
Four patients with non-inflammatory TED were treated with a complete course (8 infusions) of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for subsequent infusions every 3 weeks).
After treatment, there was a mean (SD) reduction…
Take a look at some of our conference coverage, visit our roundup section.
During a series of lectures on thyroid eye disease (TED) during the recently-concluded AAO 2020 Virtual conference, Steven M. Couch, MD, presented a to-do list for patients with…
The use of automated imaging metrics in thyroid eye disease has the potential to provide rapid clinical information that could identify visual impairments in earlier stages, potentially leading to better treatment options, according to a study.
In this study, 204 CT images of orbits in…
A new webinar, “Dealing with Thyroid Eye Disease: Patient and Physician Perspectives" provides insights into the patient and physician experience with thyroid eye disease (TED).
Hosted by the Graves’ Disease & Thyroid Foundation, the webinar covers topics such as the impact age has…